Ambrx Biopharma (Ambrx Biopharma) 3-Year EBITDA Growth Rate : 10.30% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma 3-Year EBITDA Growth Rate?

Ambrx Biopharma's EBITDA per Share for the three months ended in Jun. 2023 was $-0.68.

During the past 3 years, the average EBITDA Per Share Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ambrx Biopharma was 10.30% per year. The lowest was 10.30% per year. And the median was 10.30% per year.

Competitive Comparison of Ambrx Biopharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Ambrx Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ambrx Biopharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ambrx Biopharma's 3-Year EBITDA Growth Rate falls into.

Ambrx Biopharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ambrx Biopharma (NAS:AMAM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ambrx Biopharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ambrx Biopharma (Ambrx Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AMAM:USA

Address

10975 North Torrey Pines Road, La Jolla, CA, USA, 92037

Website

https://www.ambrx.com

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor	director, officer: President and CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan	10 percent owner	WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd.	10 percent owner	C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg	director	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans	director	C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando	officer: Chief Operating Officer	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116